442 - The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers.

Authors :: Blake, J.
Kolakowski, G.R.
Tuch, B.
Ebata, K.
Brandhuber, B.
Winski, S.
Bouhana, K.
Nanda, N.
Wu, W.I.
Parker, A.
Hamor, R.
Larsen, P.D.
Sullivan, F.
DeWolf, W.
Neitzel, N.
Wollenberg, L.
Andrews, S.
Rothenberg, S.M.
Source :: European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS144-S145. 1p.
Publication Year :: 2016

Full Text Access

Tools